Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

- PMLiVE

An exciting outlook for pre-approval access and compassionate use

How to deal with the ethical and practical considerations of the demand for promising new drugs that are in development

- PMLiVE

Novartis buys blood disease specialist Selexys

$665m deal prompted by positive phase II data for sickle cell disease therapy

- PMLiVE

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application

- PMLiVE

Change is a beast

Think about it. Change is relentless.

- PMLiVE

I, Robot: How AI is redefining the use of data in healthcare

As data moves beyond being simply ‘big’, artificial intelligence is becoming an increasingly influential set of technologies for healthcare

- PMLiVE

HealthUnlocked appoints business development director

Aji Barot joins the online social network for health

- PMLiVE

Hey You! campaign targets over 60s at high risk of stroke

Bayer launches atrial fibrillation awareness drive starring rock and roll

Mereo BioPharma appoints CFO

Richard Jones joins the rare diseases specialist

Bristol-Myers Squibb (BMS) building

NICE backs BMS leukaemia drug Sprycel

Watchdog approves blood cancer therapy for use by NHS in England and Wales

dengue fever mosquito

Dosing of GSK’s malaria vaccine due to start in 2018

WHO sanctions pilot programme in sub-Saharan Africa to begin gathering field data

- PMLiVE

Another late-stage setback tarnishes Gilead’s R&D lustre

Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links